MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.lungcan.2026.109412

Медицинская библиотека · Lung cancer (Amsterdam, Netherlands) · 2026

Vebreltinib plus EGFR-TKI for EGFR-mutated NSCLC with MET-driven resistance: A real-world study of Chinese patients.

Wang Haibo, Cai Yanyu, Jiang Kan, Zou Wei, Xiao Weijin, Xu Haipeng, Huang Yunjian, He Zhiyong, Xu Yiquan, Huang Zhangzhou

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

MET amplification/overexpression is a key resistance mechanism to EGFR-tyrosine kinase inhibitors (TKIs) in patients with EGFR-mutated non-small cell lung cancer (NSCLC). However, real-world evidence remains limited regarding the efficacy of vebreltinib plus an EGFR-TKI.

METHODS

This single-center retrospective study enrolled patients with EGFR-mutant advanced NSCLC and MET amplification/overexpression after prior EGFR-TKI failure, who received vebreltinib plus an EGFR-TKI. MET alteration was confirmed by fluorescence in situ hybridization (MET gene copy number of ≥ 5 or MET/CEP7 ratio of ≥ 2.0), next-generation sequencing (MET gene copy number of ≥ 5), or immunohistochemistry (c-MET 3 + ). The efficacy was assessed by RECIST 1.1 and safety by CTCAE 5.0.

RESULTS

Among the 49 patients, the combination therapy reported an objective response rate (ORR) of 46.9%, disease control rate of 91.8%, median progression-free survival (PFS) of 8.5 months [95% confidence interval (CI): 4.5-10.2], and median overall survival (OS) of 16.0 months (95% CI: 14.7-not reached). Patients with brain metastases (n = 23) reported an intracranial ORR of 69.6% and intracranial PFS of 9.7 months (95% CI: 5.12-not reached). Strong c-MET expression (immunohistochemistry 3 + ) was associated with significantly longer OS (not reached vs. 14.7 months,p = 0.033). Treatment-related adverse events occurred in 67.3% of patients (mostly grade 1-2), with peripheral edema as the most common type (30.6%). No permanent therapy discontinuation occurred.

CONCLUSIONS

Vebreltinib plus an EGFR-TKI demonstrates favorable efficacy and manageable safety in real-world NSCLC patients with MET-driven resistance, with notable intracranial activity. Immunohistochemistry 3 + may serve as a practical predictive biomarker.

Для цитирования: Wang Haibo, Cai Yanyu, Jiang Kan, Zou Wei, Xiao Weijin, Xu Haipeng, Huang Yunjian, He Zhiyong, Xu Yiquan, Huang Zhangzhou. Vebreltinib plus EGFR-TKI for EGFR-mutated NSCLC with MET-driven resistance: A real-world study of Chinese patients.. Lung cancer (Amsterdam, Netherlands). 2026. DOI: 10.1016/j.lungcan.2026.109412.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.